Neurocrine Biosciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kyle W. Gano
- Full Time Employees
- 2,500
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6027 Edgewood Bend Court San Diego CA United States of America 92130
- IPO Date
- May 23, 1996
- CIK
- 0000914475
- Website
- neurocrine.com
- Similar Companies
- Business
- Neurocrine Biosciences, Inc. (NBIX) is a neuroscience-focused biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for neurological, neuroendocrine and neuropsychiatric disorders. Founded in 1992 and headquartered in San Diego, California, the company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved for tardive dyskinesia in adults and chorea associated with Huntington's disease; ONGENTYS (opicapone), a catechol-O-methyltransferase inhibitor licensed for Parkinson's disease; and partnered products including ORILISSA (elagolix) and ORIAHNN for endometriosis and uterine fibroids. Its pipeline features NBI-1117568, a muscarinic receptor agonist in Phase II for schizophrenia; osavampator (formerly NBI-1065845), an AMPA positive allosteric modulator for major depressive disorder; and preclinical NLRP3 inhibitors for neuroinflammation and immunology; the company operates primarily in the United States with global partnerships. Recent developments include a January 2025 amendment to its collaboration with Takeda, granting Neurocrine exclusive worldwide rights (except Japan) to osavampator following positive End-of-Phase 2 FDA feedback; a November 2025 global licensing agreement with Pharmaron (up to $881.5 million) and collaboration with TransThera Sciences for NLRP3 inhibitors outside Greater China; and strong third-quarter 2025 financial results with INGREZZA net sales of $687 million.
Company News
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
B. Metzler seel. Sohn & Co. AG Acquires New Shares in Neurocrine Biosciences, Inc. $NBIX
Allworth Financial LP Invests $2.50 Million in Neurocrine Biosciences, Inc. $NBIX
Neurocrine Biosciences: 'House Full Of Options'
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?
BlackRock Inc. Takes $2.31 Billion Position in Neurocrine Biosciences, Inc. $NBIX
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?
14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V.
What's Going On With Neurocrine Biosciences Stock On Wednesday?
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
Glenmede Trust Co. NA Has $10.35 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX
NBIX Q2 Earnings Call Highlights: Portfolio Expansion Drives Growth
Neurocrine Biosciences, Inc. (NBIX) Q2 2026 Earnings Call Transcript